Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More
  • Additional Information
    • Publication Information:
      Elsevier BV
    • Publication Date:
      2025
    • Collection:
      ScienceDirect (Elsevier - Open Access Articles via Crossref)
    • Accession Number:
      10.1016/j.jdcr.2024.10.019
    • Online Access:
      https://doi.org/10.1016/j.jdcr.2024.10.019
      https://api.elsevier.com/content/article/PII:S235251262400417X?httpAccept=text/xml
      https://api.elsevier.com/content/article/PII:S235251262400417X?httpAccept=text/plain
    • Rights:
      https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/legal/tdmrep-license ; http://creativecommons.org/licenses/by/4.0/
    • Accession Number:
      edsbas.D44DE0DC